secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0000950170-22-002793
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Q4 revenue $33.4M (+39% YoY); FY22 guidance $125-130M (32-38% growth)
----------------------------------------------------------------------------

- Full-year 2021 revenue $94.4M (+65% YoY); net loss ($20.7M) or ($0.43)/share vs. ($4.3M) in 2020.
- Q4 gross margin 81.1% (+220 bps YoY); operating expenses $32.7M from $15.4M in Q4 2020.
- Cash $105.8M at Dec 31; FY22 revenue guided $125-130M.
- ALIGN3D clinical data: 0.9% recurrence at 12 months, 0.0% at 24 months post-Lapiplasty.
- Expanded patent portfolio: 32 granted US patents, over 30 pending applications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017022002793/0000950170-22-002793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017022002793/tmci-20220303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer